A study to find out whether the medication pasireotide is absorbed and processed the same way when given under the skin using either a reusable pen or a syringe in healthy subjects

2024-519165-22-00 Protocol SOM230-RECAG-PK-0605 Human pharmacology (Phase I) - Other Ended

Start 4 Nov 2025 · End 3 Feb 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol SOM230-RECAG-PK-0605

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 40
Countries 1
Sites 1

Post-bariatric hypoglycaemia

Key facts

Sponsor
Recordati AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
4 Nov 2025 → 3 Feb 2026
Decision date (initial)
2025-07-10
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Post-bariatric hypoglycaemia

VersionLevelCodeTermSystem organ class
21.1 PT 10059035 Postprandial hypoglycaemia 100000004861
21.1 PT 10077216 Hyperinsulinaemic hypoglycaemia 100000004861

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Recordati AG

Sponsor organisation
Recordati AG
Address
Uferstrasse 90
City
Basel Town
Postcode
4057
Country
Switzerland

Scientific contact point

Organisation
Recordati AG
Contact name
Arnd Mueller

Public contact point

Organisation
Recordati AG
Contact name
Recordati AG Clinical Trial Information Desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 40 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Nuvisan GmbH
Clinical Services, Wegenerstrasse 13, Ludwigsfeld, Neu-Ulm

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-11-04 2026-02-03 2025-11-06 2026-01-14

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-30 Germany Acceptable
2025-07-01
2025-07-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-23 Germany Acceptable
2025-07-01
2025-12-23
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-01-13 Germany Acceptable
2025-07-01
2026-01-13